Yan Leyfman, Co-Founder and Executive Director of MedNews Week, shared on LinkedIn:
“What if we could reprogram the signaling that drives T-cell lymphoma?
Relapsed/refractory T-cell lymphomas remain among the most difficult lymphoid malignancies to treat. One reason may lie in the biology of the T-cell receptor (TCR) signaling pathway itself.
Enter ITK-a key kinase involved in TCR signaling and T-cell differentiation. In a Phase 1 study of 75 patients with relapsed/refractory peripheral T-cell lymphomas, the selective ITK inhibitor soquelitinib showed encouraging activity while demonstrating >80% target occupancy at 200 mg twice daily.
The most striking finding?
Among patients who had received 1–3 prior therapies, 37% achieved durable complete or partial responses. No responses were observed in patients with >3 prior lines-highlighting the importance of treating earlier in the disease course.
But the biology may be even more interesting.
Soquelitinib shifted the immune environment toward Th1, reduced Th2 cells, and was associated with reduced T-cell exhaustion. Rather than simply killing lymphoma cells, the therapy appears to reshape the signaling and immune ecosystem that supports the disease.
This raises an important question for T-cell lymphoma:
Could targeting the signaling machinery of the malignant T cell-and simultaneously reprogramming the surrounding immune response-open a new therapeutic avenue?
For a disease with limited options after relapse, 37% durable responses in less heavily pretreated patients is a signal worth watching.”
You may also find this interesting: Peripheral T-Cell Lymphomas (PTCL): Another Evolving Lymphoma Story